drugset / Trial / NCT01080209
Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System
Non-randomizedSingle-groupSingle-blind
Summary
This study will evaluate the biodegradation of the brimonidine tartrate posterior segment drug delivery system.
Timeline
- Start
- 2010-02
- Primary completion
- 2014-02
- Completion
- 2014-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brimonidine | Unknown | 50 ug | Intravitreal |
| Subject | Brimonidine | Unknown | 100 ug | Intravitreal |
| Subject | Brimonidine | Unknown | 200 ug | Intravitreal |
| Subject | Brimonidine | Unknown | 400 ug | Intravitreal |
Indications
No indication recorded.